抗HER-2靶向治疗乳腺癌在研临床试验进展
发布时间：2018-09-14 21:11
【摘要】：目前抗人表皮生长因子受体2(human epidermal growth factor receptor-2,HER-2)阳性乳腺癌临床研究关注不同机制下靶向药物的联合、靶向药物与内分泌治疗联合、双靶向药物与化疗药物联合,目的是为未来抗HER-2临床治疗指明方向。本文着重介绍国内外在研的Ⅱ~Ⅲ期临床试验,同时介绍有较好应用潜能的靶向药物,主要包括新型小分子靶向药物、单克隆抗体靶向药物、单克隆抗体偶联物、双靶点药物联合治疗、靶向药物联合内分泌治疗、靶向联合化疗、曲妥珠单抗皮下注射制剂、HER-2肿瘤疫苗等。
[Abstract]:At present, clinical studies of anti-human epidermal growth factor receptor 2 (human epidermal growth factor receptor-2,HER-2) positive breast cancer focus on the combination of targeted drugs under different mechanisms, targeted drugs combined with endocrine therapy, dual-targeted drugs and chemotherapeutic drugs. The aim is to point out the direction of future anti-HER-2 clinical therapy. In this paper, the phase 鈪，
本文编号：2243871
[Abstract]:At present, clinical studies of anti-human epidermal growth factor receptor 2 (human epidermal growth factor receptor-2,HER-2) positive breast cancer focus on the combination of targeted drugs under different mechanisms, targeted drugs combined with endocrine therapy, dual-targeted drugs and chemotherapeutic drugs. The aim is to point out the direction of future anti-HER-2 clinical therapy. In this paper, the phase 鈪，
本文编号：2243871
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2243871.html
